The US Food and Drug Administration (FDA) has approved diroximel fumarate (Vumerity, Biogen/Alkermes) for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive disease, the companies have announced.

Similar to Tecfidera in efficacy, Vumerity, is supposed to be better tolerated than Tecfidera. Studies show that trial participants had fewer GI tract problems than on Tecfidera.

As always, once a drug is approved it won't be available until insurance companies add the medication to their formularies.

https://www.medscape.com/viewarticle/920574